{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["betulinic acid", "cancer", "irinotecan", "paclitaxel", "resveratrol", "roburic acid"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37048059", "DateCompleted": {"Year": "2023", "Month": "04", "Day": "14"}, "DateRevised": {"Year": "2023", "Month": "09", "Day": "19"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "03", "Day": "23"}], "Language": ["eng"], "ELocationID": ["986", "10.3390/cells12070986"], "Journal": {"ISSN": "2073-4409", "JournalIssue": {"Volume": "12", "Issue": "7", "PubDate": {"Year": "2023", "Month": "Mar", "Day": "23"}}, "Title": "Cells", "ISOAbbreviation": "Cells"}, "ArticleTitle": "Substances of Natural Origin in Medicine: Plants vs. Cancer.", "Abstract": {"AbstractText": ["Continuous monitoring of the population's health is the main method of learning about disease prevalence. National and international data draw attention to the persistently high rates of cancer incidence. This necessitates the intensification of efforts aimed at developing new, more effective chemotherapeutic and chemopreventive drugs. Plants represent an invaluable source of natural substances with versatile medicinal properties. Multidirectional activities exhibited by natural substances and their ability to modulate key signaling pathways, mainly related to cancer cell death, make these substances an important research direction. This review summarizes the information regarding plant-derived chemotherapeutic drugs, including their mechanisms of action, with a special focus on selected anti-cancer drugs (paclitaxel, irinotecan) approved in clinical practice. It also presents promising plant-based drug candidates currently being tested in clinical and preclinical trials (betulinic acid, resveratrol, and roburic acid)."]}, "AuthorList": [{"Identifier": ["0000-0001-9562-3582"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Doctoral School of Exact and Natural Sciences, University of Lodz, 90-237 Lodz, Poland."}, {"Identifier": [], "Affiliation": "Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland."}], "LastName": "Gieleci\u0144ska", "ForeName": "Adrianna", "Initials": "A"}, {"Identifier": ["0000-0002-8616-3825"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Doctoral School of Exact and Natural Sciences, University of Lodz, 90-237 Lodz, Poland."}, {"Identifier": [], "Affiliation": "Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland."}], "LastName": "Kciuk", "ForeName": "Mateusz", "Initials": "M"}, {"Identifier": ["0000-0003-4037-5475"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India."}], "LastName": "Mujwar", "ForeName": "Somdutt", "Initials": "S"}, {"Identifier": ["0000-0002-8146-1663"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri 38039, Turkey."}], "LastName": "Celik", "ForeName": "Ismail", "Initials": "I"}, {"Identifier": ["0000-0002-1086-3796"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Experimental Surgery, Faculty of Medicine, Medical University of Lodz, Narutowicza 60, 90-136 Lodz, Poland."}], "LastName": "Ko\u0142at", "ForeName": "Damian", "Initials": "D"}, {"Identifier": ["0000-0002-2335-3293"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Experimental Surgery, Faculty of Medicine, Medical University of Lodz, Narutowicza 60, 90-136 Lodz, Poland."}], "LastName": "Ka\u0142uzi\u0144ska-Ko\u0142at", "ForeName": "\u017baneta", "Initials": "\u017b"}, {"Identifier": ["0000-0003-2859-9839"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland."}], "LastName": "Kontek", "ForeName": "Renata", "Initials": "R"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Cells", "NlmUniqueID": "101600052", "ISSNLinking": "2073-4409"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "roburic acid"}, {"RegistryNumber": "Q369O8926L", "NameOfSubstance": "Resveratrol"}, {"RegistryNumber": "0", "NameOfSubstance": "Anticarcinogenic Agents"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["metabolism"], "DescriptorName": "Neoplasms"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Resveratrol"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Anticarcinogenic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Death"}], "CoiStatement": "The authors declare no conflict of interest. "}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Fitzmaurice C., Allen C., Barber R.M., Barregard L., Bhutta Z.A., Brenner H., Dicker D.J., Chimed-Orchir O., Dandona R., Dandona L., et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3:524\u2013548. doi: 10.1001/jamaoncol.2016.5688.", "ArticleIdList": ["10.1001/jamaoncol.2016.5688", "PMC6103527", "27918777"]}, {"Citation": "Kocarnik J.M., Compton K., Dean F.E., Fu W., Gaw B.L., Harvey J.D., Henrikson H.J., Lu D., Pennini A., Xu R., et al. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups from 2010 to 2019. JAMA Oncol. 2022;8:420\u2013444. doi: 10.1001/jamaoncol.2021.6987.", "ArticleIdList": ["10.1001/jamaoncol.2021.6987", "PMC8719276", "34967848"]}, {"Citation": "Newman D.J., Cragg G.M. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J. Nat. Prod. 2020;83:770\u2013803. doi: 10.1021/acs.jnatprod.9b01285.", "ArticleIdList": ["10.1021/acs.jnatprod.9b01285", "32162523"]}, {"Citation": "Xu Z., Eichler B., Klausner E.A., Duffy-Matzner J., Zheng W. Lead/Drug Discovery from Natural Resources. Molecules. 2022;27:8280. doi: 10.3390/molecules27238280.", "ArticleIdList": ["10.3390/molecules27238280", "PMC9736696", "36500375"]}, {"Citation": "Deng L.-J., Qi M., Li N., Lei Y.-H., Zhang D.-M., Chen J.-X. Natural Products and Their Derivatives: Promising Modulators of Tumor Immunotherapy. J. Leukoc. Biol. 2020;108:493\u2013508. doi: 10.1002/JLB.3MR0320-444R.", "ArticleIdList": ["10.1002/JLB.3MR0320-444R", "PMC7496826", "32678943"]}, {"Citation": "Newman D.J., Cragg G.M. Plant Endophytes and Epiphytes: Burgeoning Sources of Known and \u201cUnknown\u201d Cytotoxic and Antibiotic Agents? Planta Med. 2020;86:891\u2013905. doi: 10.1055/a-1095-1111.", "ArticleIdList": ["10.1055/a-1095-1111", "32023633"]}, {"Citation": "Clark G.C., Casewell N.R., Elliott C.T., Harvey A.L., Jamieson A.G., Strong P.N., Turner A.D. Friends or Foes? Emerging Impacts of Biological Toxins. Trends Biochem. Sci. 2019;44:365\u2013379. doi: 10.1016/j.tibs.2018.12.004.", "ArticleIdList": ["10.1016/j.tibs.2018.12.004", "30651181"]}, {"Citation": "Gordaliza M. Natural Products as Leads to Anticancer Drugs. Clin. Transl. Oncol. 2007;9:767\u2013776. doi: 10.1007/s12094-007-0138-9.", "ArticleIdList": ["10.1007/s12094-007-0138-9", "18158980"]}, {"Citation": "Solowey E., Lichtenstein M., Sallon S., Paavilainen H., Solowey E., Lorberboum-Galski H. Evaluating Medicinal Plants for Anticancer Activity. Sci. World J. 2014;2014:721402. doi: 10.1155/2014/721402.", "ArticleIdList": ["10.1155/2014/721402", "PMC4248331", "25478599"]}, {"Citation": "Kebebe D., Liu Y., Wu Y., Vilakhamxay M., Liu Z., Li J. Tumor-Targeting Delivery of Herb-Based Drugs with Cell-Penetrating/Tumor-Targeting Peptide-Modified Nanocarriers. Int. J. Nanomed. 2018;13:1425\u20131442. doi: 10.2147/IJN.S156616.", "ArticleIdList": ["10.2147/IJN.S156616", "PMC5849936", "29563797"]}, {"Citation": "Martino E., Casamassima G., Castiglione S., Cellupica E., Pantalone S., Papagni F., Rui M., Siciliano A.M., Collina S. Vinca Alkaloids and Analogues as Anti-Cancer Agents: Looking Back, Peering Ahead. Bioorganic Med. Chem. Lett. 2018;28:2816\u20132826. doi: 10.1016/j.bmcl.2018.06.044.", "ArticleIdList": ["10.1016/j.bmcl.2018.06.044", "30122223"]}, {"Citation": "Mosca L., Ilari A., Fazi F., Assaraf Y.G., Colotti G. Taxanes in Cancer Treatment: Activity, Chemoresistance and Its Overcoming. Drug Resist. Updates. 2021;54:100742. doi: 10.1016/j.drup.2020.100742.", "ArticleIdList": ["10.1016/j.drup.2020.100742", "33429249"]}, {"Citation": "Navarro-Hortal M.D., Varela-L\u00f3pez A., Romero-M\u00e1rquez J.M., Rivas-Garc\u00eda L., Speranza L., Battino M., Quiles J.L. Role of Flavonoids against Adriamycin Toxicity. Food Chem. Toxicol. 2020;146:111820. doi: 10.1016/j.fct.2020.111820.", "ArticleIdList": ["10.1016/j.fct.2020.111820", "33080329"]}, {"Citation": "Swinney D.C. Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines. Clin. Pharmacol. Ther. 2013;93:299\u2013301. doi: 10.1038/clpt.2012.236.", "ArticleIdList": ["10.1038/clpt.2012.236", "23511784"]}, {"Citation": "Huang M., Lu J.-J., Ding J. Natural Products in Cancer Therapy: Past, Present and Future. Nat. Prod. Bioprospect. 2021;11:5\u201313. doi: 10.1007/s13659-020-00293-7.", "ArticleIdList": ["10.1007/s13659-020-00293-7", "PMC7933288", "33389713"]}, {"Citation": "Patel P., Meghani N., Kansara K., Kumar A. Nanotherapeutics for the Treatment of Cancer and Arthritis. Curr. Drug Metab. 2019;20:430\u2013445. doi: 10.2174/1389200220666181127102720.", "ArticleIdList": ["10.2174/1389200220666181127102720", "30479211"]}, {"Citation": "Alavi M., Nokhodchi A. Micro- and Nanoformulations of Paclitaxel Based on Micelles, Liposomes, Cubosomes, and Lipid Nanoparticles: Recent Advances and Challenges. Drug Discov. Today. 2022;27:576\u2013584. doi: 10.1016/j.drudis.2021.10.007.", "ArticleIdList": ["10.1016/j.drudis.2021.10.007", "34688912"]}, {"Citation": "Mukhtar M., Bilal M., Rahdar A., Barani M., Arshad R., Behl T., Brisc C., Banica F., Bungau S. Nanomaterials for Diagnosis and Treatment of Brain Cancer: Recent Updates. Chemosensors. 2020;8:117. doi: 10.3390/chemosensors8040117.", "ArticleIdList": ["10.3390/chemosensors8040117"]}, {"Citation": "Thomford N.E., Senthebane D.A., Rowe A., Munro D., Seele P., Maroyi A., Dzobo K. Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. Int. J. Mol. Sci. 2018;19:1578. doi: 10.3390/ijms19061578.", "ArticleIdList": ["10.3390/ijms19061578", "PMC6032166", "29799486"]}, {"Citation": "Hossain R., Jain D., Khan R.A., Islam M.T., Mubarak M.S., Saikat7 A.S.M. Natural-Derived Molecules as a Potential Adjuvant in Chemotherapy: Normal Cell Protectors and Cancer Cell Sensitizers. Anticancer Agents Med. Chem. 2022;22:836\u2013850. doi: 10.2174/1871520621666210623104227.", "ArticleIdList": ["10.2174/1871520621666210623104227", "34165416"]}, {"Citation": "Diederich M. Natural Compound Inducers of Immunogenic Cell Death. Arch. Pharm. Res. 2019;42:629\u2013645. doi: 10.1007/s12272-019-01150-z.", "ArticleIdList": ["10.1007/s12272-019-01150-z", "30955159"]}, {"Citation": "Daly M.B., Pal T., Berry M.P., Buys S.S., Dickson P., Domchek S.M., Elkhanany A., Friedman S., Goggins M., Hutton M.L., et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2021;19:77\u2013102. doi: 10.6004/jnccn.2021.0001.", "ArticleIdList": ["10.6004/jnccn.2021.0001", "33406487"]}, {"Citation": "Peters U., Bien S., Zubair N. Genetic Architecture of Colorectal Cancer. Gut. 2015;64:1623\u20131636. doi: 10.1136/gutjnl-2013-306705.", "ArticleIdList": ["10.1136/gutjnl-2013-306705", "PMC4567512", "26187503"]}, {"Citation": "de Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global Burden of Cancer Attributable to Infections in 2018: A Worldwide Incidence Analysis. Lancet Glob. Health. 2020;8:e180\u2013e190. doi: 10.1016/S2214-109X(19)30488-7.", "ArticleIdList": ["10.1016/S2214-109X(19)30488-7", "31862245"]}, {"Citation": "Yoshida K., Gowers K.H.C., Lee-Six H., Chandrasekharan D.P., Coorens T., Maughan E.F., Beal K., Menzies A., Millar F.R., Anderson E., et al. Tobacco Smoking and Somatic Mutations in Human Bronchial Epithelium. Nature. 2020;578:266\u2013272. doi: 10.1038/s41586-020-1961-1.", "ArticleIdList": ["10.1038/s41586-020-1961-1", "PMC7021511", "31996850"]}, {"Citation": "Sample A., He Y.-Y. Mechanisms and Prevention of UV-Induced Melanoma. Photodermatol. Photoimmunol. Photomed. 2018;34:13\u201324. doi: 10.1111/phpp.12329.", "ArticleIdList": ["10.1111/phpp.12329", "PMC5760354", "28703311"]}, {"Citation": "Friedenreich C.M., Ryder-Burbidge C., McNeil J. Physical Activity, Obesity and Sedentary Behavior in Cancer Etiology: Epidemiologic Evidence and Biologic Mechanisms. Mol. Oncol. 2021;15:790\u2013800. doi: 10.1002/1878-0261.12772.", "ArticleIdList": ["10.1002/1878-0261.12772", "PMC7931121", "32741068"]}, {"Citation": "Schmidt S., Monk J.M., Robinson L.E., Mourtzakis M. The Integrative Role of Leptin, Oestrogen and the Insulin Family in Obesity-Associated Breast Cancer: Potential Effects of Exercise. Obes. Rev. 2015;16:473\u2013487. doi: 10.1111/obr.12281.", "ArticleIdList": ["10.1111/obr.12281", "PMC4691342", "25875578"]}, {"Citation": "Harper J.W., Elledge S.J. The DNA Damage Response: Ten Years after. Mol. Cell. 2007;28:739\u2013745. doi: 10.1016/j.molcel.2007.11.015.", "ArticleIdList": ["10.1016/j.molcel.2007.11.015", "18082599"]}, {"Citation": "Burgess R.C., Burman B., Kruhlak M.J., Misteli T. Activation of DNA Damage Response Signaling by Condensed Chromatin. Cell Rep. 2014;9:1703\u20131717. doi: 10.1016/j.celrep.2014.10.060.", "ArticleIdList": ["10.1016/j.celrep.2014.10.060", "PMC4267891", "25464843"]}, {"Citation": "Bukowski K., Kciuk M., Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int. J. Mol. Sci. 2020;21:3233. doi: 10.3390/ijms21093233.", "ArticleIdList": ["10.3390/ijms21093233", "PMC7247559", "32370233"]}, {"Citation": "Luqmani Y.A. Mechanisms of Drug Resistance in Cancer Chemotherapy. Med. Princ. Pract. 2005;14((Suppl. S1)):35\u201348. doi: 10.1159/000086183.", "ArticleIdList": ["10.1159/000086183", "16103712"]}, {"Citation": "Fu D., Calvo J.A., Samson L.D. Balancing Repair and Tolerance of DNA Damage Caused by Alkylating Agents. Nat. Rev. Cancer. 2012;12:104\u2013120. doi: 10.1038/nrc3185.", "ArticleIdList": ["10.1038/nrc3185", "PMC3586545", "22237395"]}, {"Citation": "Nussbaumer S., Bonnabry P., Veuthey J.-L., Fleury-Souverain S. Analysis of Anticancer Drugs: A Review. Talanta. 2011;85:2265\u20132289. doi: 10.1016/j.talanta.2011.08.034.", "ArticleIdList": ["10.1016/j.talanta.2011.08.034", "21962644"]}, {"Citation": "Czeczot H. Folic acid in physiology and pathology. Postepy Hig. Med. Dosw. 2008;62:405\u2013419.", "ArticleIdList": ["18772846"]}, {"Citation": "Tiwari M. Antimetabolites: Established Cancer Therapy. J. Cancer Res. Ther. 2012;8:510\u2013519. doi: 10.4103/0973-1482.106526.", "ArticleIdList": ["10.4103/0973-1482.106526", "23361267"]}, {"Citation": "Gurgul A., Lity\u0144ska A. Plant-derived compounds in the treatment of cancer. Post\u0119py Fitoter. 2017;18:203\u2013208."}, {"Citation": "Jordan M.A., Wilson L. Microtubules as a Target for Anticancer Drugs. Nat. Rev. Cancer. 2004;4:253\u2013265. doi: 10.1038/nrc1317.", "ArticleIdList": ["10.1038/nrc1317", "15057285"]}, {"Citation": "Khazir J., Mir B.A., Pilcher L., Riley D.L. Role of Plants in Anticancer Drug Discovery. Phytochem. Lett. 2014;7:173\u2013181. doi: 10.1016/j.phytol.2013.11.010.", "ArticleIdList": ["10.1016/j.phytol.2013.11.010"]}, {"Citation": "Fraschini A., Bottone M.G., Scovassi A.I., Denegri M., Risue\u00f1o M.C., Testillano P.S., Martin T.E., Biggiogera M., Pellicciari C. Changes in Extranucleolar Transcription during Actinomycin D-Induced Apoptosis. Histol. Histopathol. 2005;20:107\u2013117. doi: 10.14670/HH-20.107.", "ArticleIdList": ["10.14670/HH-20.107", "15578429"]}, {"Citation": "Kim J.Y., Kim H.S., Yoon S. Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-Resistant KBV20C Cells without Inhibiting P-Gp. Anticancer Res. 2019;39:3785\u20133793. doi: 10.21873/anticanres.13527.", "ArticleIdList": ["10.21873/anticanres.13527", "31262905"]}, {"Citation": "Murray V., Chen J.K., Chung L.H. The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA. Int. J. Mol. Sci. 2018;19:1372. doi: 10.3390/ijms19051372.", "ArticleIdList": ["10.3390/ijms19051372", "PMC5983701", "29734689"]}, {"Citation": "Rejhov\u00e1 A., Opattov\u00e1 A., \u010cumov\u00e1 A., Sl\u00edva D., Vodi\u010dka P. Natural Compounds and Combination Therapy in Colorectal Cancer Treatment. Eur. J. Med. Chem. 2018;144:582\u2013594. doi: 10.1016/j.ejmech.2017.12.039.", "ArticleIdList": ["10.1016/j.ejmech.2017.12.039", "29289883"]}, {"Citation": "Woods D., Turchi J.J. Chemotherapy Induced DNA Damage Response: Convergence of Drugs and Pathways. Cancer Biol. Ther. 2013;14:379\u2013389. doi: 10.4161/cbt.23761.", "ArticleIdList": ["10.4161/cbt.23761", "PMC3672181", "23380594"]}, {"Citation": "Griesinger F., Korol E.E., Kayaniyil S., Varol N., Ebner T., Goring S.M. Efficacy and Safety of First-Line Carboplatin-versus Cisplatin-Based Chemotherapy for Non-Small Cell Lung Cancer: A Meta-Analysis. Lung Cancer. 2019;135:196\u2013204. doi: 10.1016/j.lungcan.2019.07.010.", "ArticleIdList": ["10.1016/j.lungcan.2019.07.010", "31446995"]}, {"Citation": "Al-Mahayri Z.N., AlAhmad M.M., Ali B.R. Current Opinion on the Pharmacogenomics of Paclitaxel-Induced Toxicity. Expert Opin. Drug Metab. Toxicol. 2021;17:785\u2013801. doi: 10.1080/17425255.2021.1943358.", "ArticleIdList": ["10.1080/17425255.2021.1943358", "34128748"]}, {"Citation": "Zraik I.M., He\u00df-Busch Y. Management of chemotherapy side effects and their long-term sequelae. Urol. A. 2021;60:862\u2013871. doi: 10.1007/s00120-021-01569-7.", "ArticleIdList": ["10.1007/s00120-021-01569-7", "34185118"]}, {"Citation": "Erb M., Kliebenstein D.J. Plant Secondary Metabolites as Defenses, Regulators, and Primary Metabolites: The Blurred Functional Trichotomy. Plant Physiol. 2020;184:39\u201352. doi: 10.1104/pp.20.00433.", "ArticleIdList": ["10.1104/pp.20.00433", "PMC7479915", "32636341"]}, {"Citation": "Miralpeix B., Rischer H., H\u00e4kkinen S.T., Ritala A., Sepp\u00e4nen-Laakso T., Oksman-Caldentey K.-M., Capell T., Christou P. Metabolic Engineering of Plant Secondary Products: Which Way Forward? Curr. Pharm. Des. 2013;19:5622\u20135639. doi: 10.2174/1381612811319310016.", "ArticleIdList": ["10.2174/1381612811319310016", "23394556"]}, {"Citation": "Newman D.J. Natural Products as Leads to Potential Drugs: An Old Process or the New Hope for Drug Discovery? J. Med. Chem. 2008;51:2589\u20132599. doi: 10.1021/jm0704090.", "ArticleIdList": ["10.1021/jm0704090", "18393402"]}, {"Citation": "Li G., Lou H.-X. Strategies to Diversify Natural Products for Drug Discovery. Med. Res. Rev. 2018;38:1255\u20131294. doi: 10.1002/med.21474.", "ArticleIdList": ["10.1002/med.21474", "29064108"]}, {"Citation": "Redondo-Blanco S., Fern\u00e1ndez J., Guti\u00e9rrez-del-R\u00edo I., Villar C.J., Lomb\u00f3 F. New Insights toward Colorectal Cancer Chemotherapy Using Natural Bioactive Compounds. Front. Pharmacol. 2017;8:109. doi: 10.3389/fphar.2017.00109.", "ArticleIdList": ["10.3389/fphar.2017.00109", "PMC5348533", "28352231"]}, {"Citation": "Gallego A., Malik S., Yousefzadi M., Makhzoum A., Tremouillaux-Guiller J., Bonfill M. Taxol from Corylus Avellana: Paving the Way for a New Source of This Anti-Cancer Drug. Plant Cell Tissue Organ Cult. 2017;129:1\u201316. doi: 10.1007/s11240-016-1164-5.", "ArticleIdList": ["10.1007/s11240-016-1164-5"]}, {"Citation": "Liu K., Ding X., Deng B., Chen W. Isolation and Characterization of Endophytic Taxol-Producing Fungi from Taxus Chinensis. J. Ind. Microbiol. Biotechnol. 2009;36:1171\u20131177. doi: 10.1007/s10295-009-0598-8.", "ArticleIdList": ["10.1007/s10295-009-0598-8", "19484278"]}, {"Citation": "Mandai T., Kuroda A., Okumoto H., Nakanishi K., Mikuni K., Hara K., Hara K. A Semisynthesis of Paclitaxel via a 10-Deacetylbaccatin III Derivative Bearing a \u03b2-Keto Ester Appendage. Tetrahedron Lett. 2000;41:243\u2013246. doi: 10.1016/S0040-4039(99)02056-0.", "ArticleIdList": ["10.1016/S0040-4039(99)02056-0"]}, {"Citation": "Zhu L., Chen L. Progress in Research on Paclitaxel and Tumor Immunotherapy. Cell Mol. Biol. Lett. 2019;24:40. doi: 10.1186/s11658-019-0164-y.", "ArticleIdList": ["10.1186/s11658-019-0164-y", "PMC6567594", "31223315"]}, {"Citation": "Gebremichael Y., Chu J.-W., Voth G.A. Intrinsic Bending and Structural Rearrangement of Tubulin Dimer: Molecular Dynamics Simulations and Coarse-Grained Analysis. Biophys. J. 2008;95:2487\u20132499. doi: 10.1529/biophysj.108.129072.", "ArticleIdList": ["10.1529/biophysj.108.129072", "PMC2517022", "18515385"]}, {"Citation": "Weaver B.A. How Taxol/Paclitaxel Kills Cancer Cells. Mol. Biol. Cell. 2014;25:2677\u20132681. doi: 10.1091/mbc.e14-04-0916.", "ArticleIdList": ["10.1091/mbc.e14-04-0916", "PMC4161504", "25213191"]}, {"Citation": "Ryan S.D., Britigan E.M.C., Zasadil L.M., Witte K., Audhya A., Roopra A., Weaver B.A. Up-Regulation of the Mitotic Checkpoint Component Mad1 Causes Chromosomal Instability and Resistance to Microtubule Poisons. Proc. Natl. Acad. Sci. USA. 2012;109:E2205\u2013E2214. doi: 10.1073/pnas.1201911109.", "ArticleIdList": ["10.1073/pnas.1201911109", "PMC3421180", "22778409"]}, {"Citation": "Yamada H.Y., Gorbsky G.J. Spindle Checkpoint Function and Cellular Sensitivity to Antimitotic Drugs. Mol. Cancer Ther. 2006;5:2963\u20132969. doi: 10.1158/1535-7163.MCT-06-0319.", "ArticleIdList": ["10.1158/1535-7163.MCT-06-0319", "PMC2596631", "17172401"]}, {"Citation": "Gascoigne K.E., Taylor S.S. Cancer Cells Display Profound Intra- and Interline Variation Following Prolonged Exposure to Antimitotic Drugs. Cancer Cell. 2008;14:111\u2013122. doi: 10.1016/j.ccr.2008.07.002.", "ArticleIdList": ["10.1016/j.ccr.2008.07.002", "18656424"]}, {"Citation": "Chen J.-G., Horwitz S.B. Differential Mitotic Responses to Microtubule-Stabilizing and -Destabilizing Drugs. Cancer Res. 2002;62:1935\u20131938.", "ArticleIdList": ["11929805"]}, {"Citation": "Hornick J.E., Bader J.R., Tribble E.K., Trimble K., Breunig J.S., Halpin E.S., Vaughan K.T., Hinchcliffe E.H. Live-Cell Analysis of Mitotic Spindle Formation in Taxol-Treated Cells. Cell Motil. Cytoskelet. 2008;65:595\u2013613. doi: 10.1002/cm.20283.", "ArticleIdList": ["10.1002/cm.20283", "PMC2753270", "18481305"]}, {"Citation": "Zasadil L.M., Andersen K.A., Yeum D., Rocque G.B., Wilke L.G., Tevaarwerk A.J., Raines R.T., Burkard M.E., Weaver B.A. Cytotoxicity of Paclitaxel in Breast Cancer Is Due to Chromosome Missegregation on Multipolar Spindles. Sci. Transl. Med. 2014;6:229ra43. doi: 10.1126/scitranslmed.3007965.", "ArticleIdList": ["10.1126/scitranslmed.3007965", "PMC4176609", "24670687"]}, {"Citation": "Bernabeu E., Cagel M., Lagomarsino E., Moretton M., Chiappetta D.A. Paclitaxel: What Has Been Done and the Challenges Remain Ahead. Int. J. Pharm. 2017;526:474\u2013495. doi: 10.1016/j.ijpharm.2017.05.016.", "ArticleIdList": ["10.1016/j.ijpharm.2017.05.016", "28501439"]}, {"Citation": "Ehrlich A., Booher S., Becerra Y., Borris D.L., Figg W.D., Turner M.L., Blauvelt A. Micellar Paclitaxel Improves Severe Psoriasis in a Prospective Phase II Pilot Study. J. Am. Acad. Dermatol. 2004;50:533\u2013540. doi: 10.1016/j.jaad.2003.09.018.", "ArticleIdList": ["10.1016/j.jaad.2003.09.018", "15034502"]}, {"Citation": "Dadgar S., Ramjan Z., Floriano W.B. Paclitaxel Is an Inhibitor and Its Boron Dipyrromethene Derivative Is a Fluorescent Recognition Agent for Botulinum Neurotoxin Subtype A. J. Med. Chem. 2013;56:2791\u20132803. doi: 10.1021/jm301829h.", "ArticleIdList": ["10.1021/jm301829h", "PMC3670186", "23484537"]}, {"Citation": "Nehate C., Jain S., Saneja A., Khare V., Alam N., Dubey R.D., Gupta P.N. Paclitaxel Formulations: Challenges and Novel Delivery Options. Curr. Drug Deliv. 2014;11:666\u2013686. doi: 10.2174/1567201811666140609154949.", "ArticleIdList": ["10.2174/1567201811666140609154949", "24909147"]}, {"Citation": "Seca A.M.L., Pinto D.C.G.A. Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application. Int. J. Mol. Sci. 2018;19:263. doi: 10.3390/ijms19010263.", "ArticleIdList": ["10.3390/ijms19010263", "PMC5796209", "29337925"]}, {"Citation": "Wen G., Qu X.-X., Wang D., Chen X.-X., Tian X.-C., Gao F., Zhou X.-L. Recent Advances in Design, Synthesis and Bioactivity of Paclitaxel-Mimics. Fitoterapia. 2016;110:26\u201337. doi: 10.1016/j.fitote.2016.02.010.", "ArticleIdList": ["10.1016/j.fitote.2016.02.010", "26906104"]}, {"Citation": "Rivera E., Cianfrocca M. Overview of Neuropathy Associated with Taxanes for the Treatment of Metastatic Breast Cancer. Cancer Chemother. Pharmacol. 2015;75:659\u2013670. doi: 10.1007/s00280-014-2607-5.", "ArticleIdList": ["10.1007/s00280-014-2607-5", "PMC4365177", "25596818"]}, {"Citation": "Zhu Y., Liu N., Xiong S.D., Zheng Y.J., Chu Y.W. CD4+Foxp3+ Regulatory T-Cell Impairment by Paclitaxel Is Independent of Toll-like Receptor 4. Scand. J. Immunol. 2011;73:301\u2013308. doi: 10.1111/j.1365-3083.2011.02514.x.", "ArticleIdList": ["10.1111/j.1365-3083.2011.02514.x", "21223350"]}, {"Citation": "Sundstedt A., Celander M., Ohman M.W., Forsberg G., Hedlund G. Immunotherapy with Tumor-Targeted Superantigens (TTS) in Combination with Docetaxel Results in Synergistic Anti-Tumor Effects. Int. Immunopharmacol. 2009;9:1063\u20131070. doi: 10.1016/j.intimp.2009.04.013.", "ArticleIdList": ["10.1016/j.intimp.2009.04.013", "19410661"]}, {"Citation": "Lesterhuis W.J., Punt C.J.A., Hato S.V., Eleveld-Trancikova D., Jansen B.J.H., Nierkens S., Schreibelt G., de Boer A., Van Herpen C.M.L., Kaanders J.H., et al. Platinum-Based Drugs Disrupt STAT6-Mediated Suppression of Immune Responses against Cancer in Humans and Mice. J. Clin. Invest. 2011;121:3100\u20133108. doi: 10.1172/JCI43656.", "ArticleIdList": ["10.1172/JCI43656", "PMC3148725", "21765211"]}, {"Citation": "Haque S., Morris J.C. Transforming Growth Factor-\u03b2: A Therapeutic Target for Cancer. Hum. Vaccines Immunother. 2017;13:1741\u20131750. doi: 10.1080/21645515.2017.1327107.", "ArticleIdList": ["10.1080/21645515.2017.1327107", "PMC5557219", "28575585"]}, {"Citation": "Zhang L., Dermawan K., Jin M., Liu R., Zheng H., Xu L., Zhang Y., Cai Y., Chu Y., Xiong S. Differential Impairment of Regulatory T Cells Rather than Effector T Cells by Paclitaxel-Based Chemotherapy. Clin. Immunol. 2008;129:219\u2013229. doi: 10.1016/j.clim.2008.07.013.", "ArticleIdList": ["10.1016/j.clim.2008.07.013", "18771959"]}, {"Citation": "Mazieres J., Kowalski D., Luft A., Vicente D., Tafreshi A., G\u00fcm\u00fc\u015f M., Laktionov K., Hermes B., Cicin I., Rodr\u00edguez-Cid J., et al. Health-Related Quality of Life with Carboplatin-Paclitaxel or Nab-Paclitaxel with or without Pembrolizumab in Patients with Metastatic Squamous Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2020;38:271\u2013280. doi: 10.1200/JCO.19.01348.", "ArticleIdList": ["10.1200/JCO.19.01348", "31751163"]}, {"Citation": "Park J., Park J.E., Hedrick V.E., Wood K.V., Bonham C., Lee W., Yeo Y. A Comparative In Vivo Study of Albumin-Coated Paclitaxel Nanocrystals and Abraxane. Small. 2018;14:e1703670. doi: 10.1002/smll.201703670.", "ArticleIdList": ["10.1002/smll.201703670", "PMC5908729", "29570231"]}, {"Citation": "Cheng M., Liu Q., Gan T., Fang Y., Yue P., Sun Y., Jin Y., Feng J., Tu L. Nanocrystal-Loaded Micelles for the Enhanced In Vivo Circulation of Docetaxel. Molecules. 2021;26:4481. doi: 10.3390/molecules26154481.", "ArticleIdList": ["10.3390/molecules26154481", "PMC8348076", "34361634"]}, {"Citation": "Mout L., van Royen M.E., de Ridder C., Stuurman D., van de Geer W.S., Marques R., Buck S.A.J., French P.J., van de Werken H.J.G., Mathijssen R.H.J., et al. Continued Androgen Signalling Inhibition Improves Cabazitaxel Efficacy in Prostate Cancer. EBioMedicine. 2021;73:103681. doi: 10.1016/j.ebiom.2021.103681.", "ArticleIdList": ["10.1016/j.ebiom.2021.103681", "PMC8586743", "34749299"]}, {"Citation": "Pommier Y. Drugging Topoisomerases: Lessons and Challenges. ACS Chem. Biol. 2013;8:82\u201395. doi: 10.1021/cb300648v.", "ArticleIdList": ["10.1021/cb300648v", "PMC3549721", "23259582"]}, {"Citation": "Kciuk M., Marciniak B., Kontek R. Irinotecan\u2014Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview. Int. J. Mol. Sci. 2020;21:4919. doi: 10.3390/ijms21144919.", "ArticleIdList": ["10.3390/ijms21144919", "PMC7404108", "32664667"]}, {"Citation": "Guemei A.A., Cottrell J., Band R., Hehman H., Prudhomme M., Pavlov M.V., Grem J.L., Ismail A.S., Bowen D., Taylor R.E., et al. Human Plasma Carboxylesterase and Butyrylcholinesterase Enzyme Activity: Correlations with SN-38 Pharmacokinetics during a Prolonged Infusion of Irinotecan. Cancer Chemother. Pharmacol. 2001;47:283\u2013290. doi: 10.1007/s002800000258.", "ArticleIdList": ["10.1007/s002800000258", "11345644"]}, {"Citation": "Haaz M.C., Rivory L., Jantet S., Ratanasavanh D., Robert J. Glucuronidation of SN-38, the Active Metabolite of Irinotecan, by Human Hepatic Microsomes. Pharmacol. Toxicol. 1997;80:91\u201396. doi: 10.1111/j.1600-0773.1997.tb00289.x.", "ArticleIdList": ["10.1111/j.1600-0773.1997.tb00289.x", "9060040"]}, {"Citation": "Yamamoto M., Kurita A., Asahara T., Takakura A., Katono K., Iwasaki M., Ryuge S., Wada M., Onoda S., Yanaihara T., et al. Metabolism of Irinotecan and Its Active Metabolite SN-38 by Intestinal Microflora in Rats. Oncol. Rep. 2008;20:727\u2013730.", "ArticleIdList": ["18813810"]}, {"Citation": "Bailly C. Irinotecan: 25 Years of Cancer Treatment. Pharmacol. Res. 2019;148:104398. doi: 10.1016/j.phrs.2019.104398.", "ArticleIdList": ["10.1016/j.phrs.2019.104398", "31415916"]}, {"Citation": "Bush N.G., Evans-Roberts K., Maxwell A. DNA Topoisomerases. EcoSal Plus. 2015;6 doi: 10.1128/ecosalplus.ESP-0010-2014.", "ArticleIdList": ["10.1128/ecosalplus.ESP-0010-2014", "26435256"]}, {"Citation": "Pommier Y., Sun Y., Huang S.-Y.N., Nitiss J.L. Roles of Eukaryotic Topoisomerases in Transcription, Replication and Genomic Stability. Nat. Rev. Mol. Cell Biol. 2016;17:703\u2013721. doi: 10.1038/nrm.2016.111.", "ArticleIdList": ["10.1038/nrm.2016.111", "PMC9248348", "27649880"]}, {"Citation": "McKie S.J., Neuman K.C., Maxwell A. DNA Topoisomerases: Advances in Understanding of Cellular Roles and Multi-Protein Complexes via Structure-Function Analysis. BioEssays. 2021;43:2000286. doi: 10.1002/bies.202000286.", "ArticleIdList": ["10.1002/bies.202000286", "PMC7614492", "33480441"]}, {"Citation": "Baker N.M., Rajan R., Mondrag\u00f3n A. Structural Studies of Type I Topoisomerases. Nucleic Acids Res. 2009;37:693\u2013701. doi: 10.1093/nar/gkn1009.", "ArticleIdList": ["10.1093/nar/gkn1009", "PMC2647283", "19106140"]}, {"Citation": "Xu Y., Villalona-Calero M.A. Irinotecan: Mechanisms of Tumor Resistance and Novel Strategies for Modulating Its Activity. Ann. Oncol. 2002;13:1841\u20131851. doi: 10.1093/annonc/mdf337.", "ArticleIdList": ["10.1093/annonc/mdf337", "12453851"]}, {"Citation": "Khageh Hosseini S., Kolterer S., Steiner M., von Manstein V., Gerlach K., Trojan J., Waidmann O., Zeuzem S., Schulze J.O., Hahn S., et al. Camptothecin and Its Analog SN-38, the Active Metabolite of Irinotecan, Inhibit Binding of the Transcriptional Regulator and Oncoprotein FUBP1 to Its DNA Target Sequence FUSE. Biochem. Pharmacol. 2017;146:53\u201362. doi: 10.1016/j.bcp.2017.10.003.", "ArticleIdList": ["10.1016/j.bcp.2017.10.003", "29031818"]}, {"Citation": "Zhou W., Chung Y.J., Parrilla Castellar E.R., Zheng Y., Chung H.-J., Bandle R., Liu J., Tessarollo L., Batchelor E., Aplan P.D., et al. Far Upstream Element Binding Protein Plays a Crucial Role in Embryonic Development, Hematopoiesis, and Stabilizing Myc Expression Levels. Am. J. Pathol. 2016;186:701\u2013715. doi: 10.1016/j.ajpath.2015.10.028.", "ArticleIdList": ["10.1016/j.ajpath.2015.10.028", "PMC4816710", "26774856"]}, {"Citation": "Hwang I., Cao D., Na Y., Kim D.-Y., Zhang T., Yao J., Oh H., Hu J., Zheng H., Yao Y., et al. Far Upstream Element-Binding Protein 1 Regulates LSD1 Alternative Splicing to Promote Terminal Differentiation of Neural Progenitors. Stem Cell Rep. 2018;10:1208\u20131221. doi: 10.1016/j.stemcr.2018.02.013.", "ArticleIdList": ["10.1016/j.stemcr.2018.02.013", "PMC5998560", "29606613"]}, {"Citation": "Takeba Y., Kumai T., Matsumoto N., Nakaya S., Tsuzuki Y., Yanagida Y., Kobayashi S. Irinotecan Activates P53 with Its Active Metabolite, Resulting in Human Hepatocellular Carcinoma Apoptosis. J. Pharmacol. Sci. 2007;104:232\u2013242. doi: 10.1254/jphs.FP0070442.", "ArticleIdList": ["10.1254/jphs.FP0070442", "17609585"]}, {"Citation": "Was H., Czarnecka J., Kominek A., Barszcz K., Bernas T., Piwocka K., Kaminska B. Some Chemotherapeutics-Treated Colon Cancer Cells Display a Specific Phenotype Being a Combination of Stem-like and Senescent Cell Features. Cancer Biol. Ther. 2017;19:63\u201375. doi: 10.1080/15384047.2017.1385675.", "ArticleIdList": ["10.1080/15384047.2017.1385675", "PMC5790359", "29053388"]}, {"Citation": "Fuchs C., Mitchell E.P., Hoff P.M. Irinotecan in the Treatment of Colorectal Cancer. Cancer Treat. Rev. 2006;32:491\u2013503. doi: 10.1016/j.ctrv.2006.07.001.", "ArticleIdList": ["10.1016/j.ctrv.2006.07.001", "16959432"]}, {"Citation": "Pectasides D., Mylonakis N., Farmakis D., Nikolaou M., Koumpou M., Katselis I., Gaglia A., Kostopoulou V., Karabelis A., Kosmas C. Irinotecan and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer, Previously Treated with Cisplatin-Based Chemotherapy. A Phase II Study. Anticancer Res. 2003;23:4205\u20134211.", "ArticleIdList": ["14666626"]}, {"Citation": "Makiyama A., Arimizu K., Hirano G., Makiyama C., Matsushita Y., Shirakawa T., Ohmura H., Komoda M., Uchino K., Inadomi K., et al. Irinotecan Monotherapy as Third-Line or Later Treatment in Advanced Gastric Cancer. Gastric Cancer. 2018;21:464\u2013472. doi: 10.1007/s10120-017-0759-9.", "ArticleIdList": ["10.1007/s10120-017-0759-9", "28799048"]}, {"Citation": "Gershenson D.M. Irinotecan in Epithelial Ovarian Cancer. Oncology. 2002;16:29\u201331.", "ArticleIdList": ["12109803"]}, {"Citation": "Reita D., Bour C., Benbrika R., Groh A., Pencreach E., Gu\u00e9rin E., Guenot D. Synergistic Anti-Tumor Effect of MTOR Inhibitors with Irinotecan on Colon Cancer Cells. Cancers. 2019;11:1581. doi: 10.3390/cancers11101581.", "ArticleIdList": ["10.3390/cancers11101581", "PMC6826690", "31627299"]}, {"Citation": "Lang D.K., Kaur R., Arora R., Saini B., Arora S. Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview. Anticancer Agents Med. Chem. 2020;20:2150\u20132168. doi: 10.2174/1871520620666200705214917.", "ArticleIdList": ["10.2174/1871520620666200705214917", "32628593"]}, {"Citation": "Lara P.N., Natale R., Crowley J., Lenz H.J., Redman M.W., Carleton J.E., Jett J., Langer C.J., Kuebler J.P., Dakhil S.R., et al. Phase III Trial of Irinotecan/Cisplatin Compared with Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results from SWOG S0124. J. Clin. Oncol. 2009;27:2530\u20132535. doi: 10.1200/JCO.2008.20.1061.", "ArticleIdList": ["10.1200/JCO.2008.20.1061", "PMC2684855", "19349543"]}, {"Citation": "Wang W., Tse-Dinh Y.-C. Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy. Curr. Top. Med. Chem. 2019;19:730\u2013740. doi: 10.2174/1568026619666190401113350.", "ArticleIdList": ["10.2174/1568026619666190401113350", "30931861"]}, {"Citation": "Wang-Gillam A., Hubner R.A., Siveke J.T., Von Hoff D.D., Belanger B., de Jong F.A., Mirakhur B., Chen L.-T. NAPOLI-1 Phase 3 Study of Liposomal Irinotecan in Metastatic Pancreatic Cancer: Final Overall Survival Analysis and Characteristics of Long-Term Survivors. Eur. J. Cancer. 2019;108:78\u201387. doi: 10.1016/j.ejca.2018.12.007.", "ArticleIdList": ["10.1016/j.ejca.2018.12.007", "30654298"]}, {"Citation": "Bernards N., Ventura M., Fricke I.B., Hendriks B.S., Fitzgerald J., Lee H., Zheng J. Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis. Mol. Pharm. 2018;15:4132\u20134138. doi: 10.1021/acs.molpharmaceut.8b00540.", "ArticleIdList": ["10.1021/acs.molpharmaceut.8b00540", "30059232"]}, {"Citation": "Zhu S., Dou M., Huang G. Intratumoral Injection Administration of Irinotecan-Loaded Microspheres: In Vitro and In Vivo Evaluation. AAPS PharmSciTech. 2018;19:3829\u20133838. doi: 10.1208/s12249-018-1167-0.", "ArticleIdList": ["10.1208/s12249-018-1167-0", "30280351"]}, {"Citation": "Tanaka K., Maeda N., Osuga K., Higashi Y., Hayashi A., Hori Y., Kishimoto K., Morii E., Ohashi F., Tomiyama N. In Vivo Evaluation of Irinotecan-Loaded QuadraSphere Microspheres for Use in Chemoembolization of VX2 Liver Tumors. J. Vasc. Interv. Radiol. 2014;25:1727\u20131735. doi: 10.1016/j.jvir.2014.07.012.", "ArticleIdList": ["10.1016/j.jvir.2014.07.012", "25239839"]}, {"Citation": "Bhaskaran N.A., Jitta S.R., Salwa, Cheruku S., Kumar N., Kumar L. Orally Delivered Solid Lipid Nanoparticles of Irinotecan Coupled with Chitosan Surface Modification to Treat Colon Cancer: Preparation, in-Vitro and in-Vivo Evaluations. Int. J. Biol. Macromol. 2022;211:301\u2013315. doi: 10.1016/j.ijbiomac.2022.05.060.", "ArticleIdList": ["10.1016/j.ijbiomac.2022.05.060", "35568152"]}, {"Citation": "Hordyjewska A., Ostapiuk A., Horecka A., Kurzepa J. Betulin and Betulinic Acid: Triterpenoids Derivatives with a Powerful Biological Potential. Phytochem. Rev. 2019;18:929\u2013951. doi: 10.1007/s11101-019-09623-1.", "ArticleIdList": ["10.1007/s11101-019-09623-1"]}, {"Citation": "Dr\u0105g-Zalesi\u0144ska M., Borska S. Betulin and its derivatives\u2013precursors of new drugs. World Sci. News. 2019;127:123\u2013138."}, {"Citation": "Mukherjee D., Kumar N.S., Khatua T., Mukherjee P.K. Rapid Validated HPTLC Method for Estimation of Betulinic Acid in Nelumbo Nucifera (Nymphaeaceae) Rhizome Extract. Phytochem. Anal. 2010;21:556\u2013560. doi: 10.1002/pca.1232.", "ArticleIdList": ["10.1002/pca.1232", "21043041"]}, {"Citation": "Kim H.-I., Quan F.-S., Kim J.-E., Lee N.-R., Kim H.J., Jo S.J., Lee C.-M., Jang D.S., Inn K.-S. Inhibition of Estrogen Signaling through Depletion of Estrogen Receptor Alpha by Ursolic Acid and Betulinic Acid from Prunella Vulgaris Var. Lilacina. Biochem. Biophys. Res. Commun. 2014;451:282\u2013287. doi: 10.1016/j.bbrc.2014.07.115.", "ArticleIdList": ["10.1016/j.bbrc.2014.07.115", "25088993"]}, {"Citation": "Kim D.S.H.L., Chen Z., Nguyen V.T., Pezzuto J.M., Qiu S., Lu Z.-Z. A Concise Semi-Synthetic Approach to Betulinic Acid from Betulin. Synth. Commun. 1997;27:1607\u20131612. doi: 10.1080/00397919708006099.", "ArticleIdList": ["10.1080/00397919708006099"]}, {"Citation": "Csuk R., Schmuck K., Sch\u00e4fer R. A Practical Synthesis of Betulinic Acid. Tetrahedron Lett. 2006;47:8769\u20138770. doi: 10.1016/j.tetlet.2006.10.004.", "ArticleIdList": ["10.1016/j.tetlet.2006.10.004"]}, {"Citation": "Chen Q., Liu J., Zhang H., He G., Fu M. The Betulinic Acid Production from Betulin through Biotransformation by Fungi. Enzym. Microb. Technol. 2009;45:175\u2013180. doi: 10.1016/j.enzmictec.2009.06.005.", "ArticleIdList": ["10.1016/j.enzmictec.2009.06.005"]}, {"Citation": "Liu J., Fu M.L., Chen Q.H. Biotransformation Optimization of Betulin into Betulinic Acid Production Catalysed by Cultured Armillaria Luteo-Virens Sacc ZJUQH100-6 Cells. J. Appl. Microbiol. 2011;110:90\u201397. doi: 10.1111/j.1365-2672.2010.04857.x.", "ArticleIdList": ["10.1111/j.1365-2672.2010.04857.x", "20860772"]}, {"Citation": "Li J., Zhang Y. Increase of Betulinic Acid Production in Saccharomyces Cerevisiae by Balancing Fatty Acids and Betulinic Acid Forming Pathways. Appl. Microbiol. Biotechnol. 2014;98:3081\u20133089. doi: 10.1007/s00253-013-5461-1.", "ArticleIdList": ["10.1007/s00253-013-5461-1", "24389702"]}, {"Citation": "Pitt J.M., Marabelle A., Eggermont A., Soria J.-C., Kroemer G., Zitvogel L. Targeting the Tumor Microenvironment: Removing Obstruction to Anticancer Immune Responses and Immunotherapy. Ann. Oncol. 2016;27:1482\u20131492. doi: 10.1093/annonc/mdw168.", "ArticleIdList": ["10.1093/annonc/mdw168", "27069014"]}, {"Citation": "Gajewski T.F., Schreiber H., Fu Y.-X. Innate and Adaptive Immune Cells in the Tumor Microenvironment. Nat. Immunol. 2013;14:1014\u20131022. doi: 10.1038/ni.2703.", "ArticleIdList": ["10.1038/ni.2703", "PMC4118725", "24048123"]}, {"Citation": "Jafari Khataylou Y., Ahmadi Afshar S., Mirzakhani N. Betulinic Acid Reduces the Complications of Autoimmune Diabetes on the Body and Kidney through Effecting on Inflammatory Cytokines in C57BL/6 Mice. Vet. Res. Forum. 2021;12:203\u2013210. doi: 10.30466/vrf.2019.101178.2409.", "ArticleIdList": ["10.30466/vrf.2019.101178.2409", "PMC8328255", "34345387"]}, {"Citation": "Costa J.F.O., Barbosa-Filho J.M., Maia G.L.D.A., Guimar\u00e3es E.T., Meira C.S., Ribeiro-dos-Santos R., de Carvalho L.C.P., Soares M.B.P. Potent Anti-Inflammatory Activity of Betulinic Acid Treatment in a Model of Lethal Endotoxemia. Int. Immunopharmacol. 2014;23:469\u2013474. doi: 10.1016/j.intimp.2014.09.021.", "ArticleIdList": ["10.1016/j.intimp.2014.09.021", "25281393"]}, {"Citation": "Hinz M., Scheidereit C. The I\u03baB Kinase Complex in NF-\u039aB Regulation and Beyond. EMBO Rep. 2014;15:46\u201361. doi: 10.1002/embr.201337983.", "ArticleIdList": ["10.1002/embr.201337983", "PMC4303448", "24375677"]}, {"Citation": "Janssen-Heininger Y.M., Poynter M.E., Baeuerle P.A. Recent Advances towards Understanding Redox Mechanisms in the Activation of Nuclear Factor KappaB. Free Radic. Biol. Med. 2000;28:1317\u20131327. doi: 10.1016/S0891-5849(00)00218-5.", "ArticleIdList": ["10.1016/S0891-5849(00)00218-5", "10924851"]}, {"Citation": "Viji V., Helen A., Luxmi V.R. Betulinic Acid Inhibits Endotoxin-Stimulated Phosphorylation Cascade and pro-Inflammatory Prostaglandin E2 Production in Human Peripheral Blood Mononuclear Cells. Br. J. Pharmacol. 2011;162:1291\u20131303. doi: 10.1111/j.1476-5381.2010.01112.x.", "ArticleIdList": ["10.1111/j.1476-5381.2010.01112.x", "PMC3058162", "21077850"]}, {"Citation": "Wang H., Wang H., Ge L., Zhao Y., Zhu K., Chen Z., Wu Q., Xin Y., Guo J. Betulinic Acid Targets Drug-Resistant Human Gastric Cancer Cells by Inducing Autophagic Cell Death, Suppresses Cell Migration and Invasion, and Modulates the ERK/MEK Signaling Pathway. Acta Biochim. Pol. 2021;69:25\u201330. doi: 10.18388/abp.2020_5530.", "ArticleIdList": ["10.18388/abp.2020_5530", "34860480"]}, {"Citation": "Pisha E., Chai H., Lee I.S., Chagwedera T.E., Farnsworth N.R., Cordell G.A., Beecher C.W., Fong H.H., Kinghorn A.D., Brown D.M. Discovery of Betulinic Acid as a Selective Inhibitor of Human Melanoma That Functions by Induction of Apoptosis. Nat. Med. 1995;1:1046\u20131051. doi: 10.1038/nm1095-1046.", "ArticleIdList": ["10.1038/nm1095-1046", "7489361"]}, {"Citation": "Lee D., Lee S.R., Kang K.S., Ko Y., Pang C., Yamabe N., Kim K.H. Betulinic Acid Suppresses Ovarian Cancer Cell Proliferation through Induction of Apoptosis. Biomolecules. 2019;9:257. doi: 10.3390/biom9070257.", "ArticleIdList": ["10.3390/biom9070257", "PMC6681197", "31277238"]}, {"Citation": "Luo R., Fang D., Chu P., Wu H., Zhang Z., Tang Z. Multiple Molecular Targets in Breast Cancer Therapy by Betulinic Acid. Biomed. Pharmacother. 2016;84:1321\u20131330. doi: 10.1016/j.biopha.2016.10.018.", "ArticleIdList": ["10.1016/j.biopha.2016.10.018", "27810789"]}, {"Citation": "Li L., Davie J.R. The Role of Sp1 and Sp3 in Normal and Cancer Cell Biology. Ann. Anat.-Anat. Anz. 2010;192:275\u2013283. doi: 10.1016/j.aanat.2010.07.010.", "ArticleIdList": ["10.1016/j.aanat.2010.07.010", "20810260"]}, {"Citation": "Melincovici C.S., Bo\u015fca A.B., \u015eu\u015fman S., M\u0103rginean M., Mihu C., Istrate M., Moldovan I.M., Roman A.L., Mihu C.M. Vascular Endothelial Growth Factor (VEGF)\u2014Key Factor in Normal and Pathological Angiogenesis. Rom. J. Morphol. Embryol. 2018;59:455\u2013467.", "ArticleIdList": ["30173249"]}, {"Citation": "Fan H., Shao S.L., He M.Q., Huang X., Zhang W.W., Zhang Z.Z. Effects of betulinic acid on apoptosis of human gastric cancer MGC-803 cells. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2021;37:419\u2013422. doi: 10.12047/j.cjap.6078.2021.039.", "ArticleIdList": ["10.12047/j.cjap.6078.2021.039", "34374264"]}, {"Citation": "Schwartz L.M. Autophagic Cell Death during Development\u2014Ancient and Mysterious. Front. Cell Dev. Biol. 2021;9:656370. doi: 10.3389/fcell.2021.656370.", "ArticleIdList": ["10.3389/fcell.2021.656370", "PMC8063034", "33898457"]}, {"Citation": "Luo J. Autophagy and Ethanol Neurotoxicity. Autophagy. 2015;10:2099\u20132108. doi: 10.4161/15548627.2014.981916.", "ArticleIdList": ["10.4161/15548627.2014.981916", "PMC4502825", "25484085"]}, {"Citation": "Levine B., Kroemer G. Autophagy in the Pathogenesis of Disease. Cell. 2008;132:27\u201342. doi: 10.1016/j.cell.2007.12.018.", "ArticleIdList": ["10.1016/j.cell.2007.12.018", "PMC2696814", "18191218"]}, {"Citation": "Dere\u0144-Wagemann I., Kie\u0142bi\u0144ski M., Kuliczkowski K. Autofagia\u2013Proces o Dw\u00f3ch Obliczach. Acta Haematol. Pol. 2013;44:383\u2013391. doi: 10.1016/j.achaem.2013.05.003.", "ArticleIdList": ["10.1016/j.achaem.2013.05.003"]}, {"Citation": "Wang G., Wang Y.-Z., Yu Y., Yin P.-H., Xu K. The Antitumor Activity of Betulinic Acid-Loaded Nanoliposomes against Colorectal Cancer In Vitro and In Vivo via Glycolytic and Glutaminolytic Pathways. J. Biomed. Nanotechnol. 2020;16:235\u2013251. doi: 10.1166/jbn.2020.2888.", "ArticleIdList": ["10.1166/jbn.2020.2888", "32252884"]}, {"Citation": "Zhao Y., Li Y., Zhang R., Wang F., Wang T., Jiao Y. The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy. OncoTargets Ther. 2020;13:5429\u20135441. doi: 10.2147/OTT.S254995.", "ArticleIdList": ["10.2147/OTT.S254995", "PMC7295539", "32606760"]}, {"Citation": "Liebscher G., Vanchangiri K., Mueller T., Feige K., Cavalleri J.-M.V., Paschke R. In Vitro Anticancer Activity of Betulinic Acid and Derivatives Thereof on Equine Melanoma Cell Lines from Grey Horses and in Vivo Safety Assessment of the Compound NVX-207 in Two Horses. Chem. Biol. Interact. 2016;246:20\u201329. doi: 10.1016/j.cbi.2016.01.002.", "ArticleIdList": ["10.1016/j.cbi.2016.01.002", "26772157"]}, {"Citation": "Willmann M., Wacheck V., Buckley J., Nagy K., Thalhammer J., Paschke R., Triche T., Jansen B., Selzer E. Characterization of NVX-207, a Novel Betulinic Acid-Derived Anti-Cancer Compound. Eur. J. Clin. Invest. 2009;39:384\u2013394. doi: 10.1111/j.1365-2362.2009.02105.x.", "ArticleIdList": ["10.1111/j.1365-2362.2009.02105.x", "19309323"]}, {"Citation": "Prados M.E., Garc\u00eda-Mart\u00edn A., Unciti-Broceta J.D., Palomares B., Collado J.A., Minassi A., Calzado M.A., Appendino G., Mu\u00f1oz E. Betulinic Acid Hydroxamate Prevents Colonic Inflammation and Fibrosis in Murine Models of Inflammatory Bowel Disease. Acta Pharmacol. Sin. 2021;42:1124\u20131138. doi: 10.1038/s41401-020-0497-0.", "ArticleIdList": ["10.1038/s41401-020-0497-0", "PMC8209138", "32811965"]}, {"Citation": "Wang G., Yang Y., Yi D., Yuan L., Yin P.-H., Ke X., Jun-Jie W., Tao M.-F. Eudragit S100 Prepared PH-Responsive Liposomes-Loaded Betulinic Acid against Colorectal Cancer in Vitro and in Vivo. J. Liposome Res. 2022;32:250\u2013264. doi: 10.1080/08982104.2021.1999974.", "ArticleIdList": ["10.1080/08982104.2021.1999974", "34895013"]}, {"Citation": "Dutta D., Paul B., Mukherjee B., Mondal L., Sen S., Chowdhury C., Debnath M.C. Nanoencapsulated Betulinic Acid Analogue Distinctively Improves Colorectal Carcinoma in Vitro and in Vivo. Sci. Rep. 2019;9:11506. doi: 10.1038/s41598-019-47743-y.", "ArticleIdList": ["10.1038/s41598-019-47743-y", "PMC6687831", "31395908"]}, {"Citation": "Weber L.A., Funtan A., Paschke R., Delarocque J., Kalbitz J., Mei\u00dfner J., Feige K., Kietzmann M., Cavalleri J.-M.V. In Vitro Assessment of Triterpenoids NVX-207 and Betulinyl-Bis-Sulfamate as a Topical Treatment for Equine Skin Cancer. PLoS ONE. 2020;15:e0241448. doi: 10.1371/journal.pone.0241448.", "ArticleIdList": ["10.1371/journal.pone.0241448", "PMC7643960", "33151949"]}, {"Citation": "Weber L.A., Delarocque J., Feige K., Kietzmann M., Kalbitz J., Mei\u00dfner J., Paschke R., Cavalleri J.-M.V. Effects of Topically Applied Betulinic Acid and NVX-207 on Melanocytic Tumors in 18 Horses. Animals. 2021;11:3250. doi: 10.3390/ani11113250.", "ArticleIdList": ["10.3390/ani11113250", "PMC8614291", "34827981"]}, {"Citation": "Langcake P., Pryce R.J. The Production of Resveratrol by Vitis Vinifera and Other Members of the Vitaceae as a Response to Infection or Injury. Physiol. Plant Pathol. 1976;9:77\u201386. doi: 10.1016/0048-4059(76)90077-1.", "ArticleIdList": ["10.1016/0048-4059(76)90077-1"]}, {"Citation": "Pervaiz S. Chemotherapeutic Potential of the Chemopreventive Phytoalexin Resveratrol. Drug Resist. Updates. 2004;7:333\u2013344. doi: 10.1016/j.drup.2004.11.001.", "ArticleIdList": ["10.1016/j.drup.2004.11.001", "15790544"]}, {"Citation": "Biesalski H.K. Polyphenols and Inflammation: Basic Interactions. Curr. Opin. Clin. Nutr. Metab. Care. 2007;10:724\u2013728. doi: 10.1097/MCO.0b013e3282f0cef2.", "ArticleIdList": ["10.1097/MCO.0b013e3282f0cef2", "18089954"]}, {"Citation": "Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of Resveratrol in Prevention and Therapy of Cancer: Preclinical and Clinical Studies. Anticancer Res. 2004;24:2783\u20132840.", "ArticleIdList": ["15517885"]}, {"Citation": "Hurst W.J., Glinski J.A., Miller K.B., Apgar J., Davey M.H., Stuart D.A. Survey of the Trans-Resveratrol and Trans-Piceid Content of Cocoa-Containing and Chocolate Products. J. Agric. Food Chem. 2008;56:8374\u20138378. doi: 10.1021/jf801297w.", "ArticleIdList": ["10.1021/jf801297w", "18759443"]}, {"Citation": "Shin S.-Y., Jung S.-M., Kim M.-D., Han N.S., Seo J.-H. Production of Resveratrol from Tyrosine in Metabolically Engineered Saccharomyces Cerevisiae. Enzym. Microb. Technol. 2012;51:211\u2013216. doi: 10.1016/j.enzmictec.2012.06.005.", "ArticleIdList": ["10.1016/j.enzmictec.2012.06.005", "22883555"]}, {"Citation": "Vian M.A., Tomao V., Gallet S., Coulomb P.O., Lacombe J.M. Simple and Rapid Method for Cis- and Trans-Resveratrol and Piceid Isomers Determination in Wine by High-Performance Liquid Chromatography Using Chromolith Columns. J. Chromatogr. A. 2005;1085:224\u2013229. doi: 10.1016/j.chroma.2005.05.083.", "ArticleIdList": ["10.1016/j.chroma.2005.05.083", "16106702"]}, {"Citation": "Stivala L.A., Savio M., Carafoli F., Perucca P., Bianchi L., Maga G., Forti L., Pagnoni U.M., Albini A., Prosperi E., et al. Specific Structural Determinants Are Responsible for the Antioxidant Activity and the Cell Cycle Effects of Resveratrol. J. Biol. Chem. 2001;276:22586\u201322594. doi: 10.1074/jbc.M101846200.", "ArticleIdList": ["10.1074/jbc.M101846200", "11316812"]}, {"Citation": "Colin D.J., Limagne E., Ragot K., Lizard G., Ghiringhelli F., Solary \u00c9., Chauffert B., Latruffe N., Delmas D. The Role of Reactive Oxygen Species and Subsequent DNA-Damage Response in the Emergence of Resistance towards Resveratrol in Colon Cancer Models. Cell Death Dis. 2014;5:e1533. doi: 10.1038/cddis.2014.486.", "ArticleIdList": ["10.1038/cddis.2014.486", "PMC4260744", "25412311"]}, {"Citation": "Kulesza M., Dansonka-Mieszkowska A., Pie\u0144kowska-Grela B. Napraw albo zgi\u0144\u2013rola bia\u0142ka p53 w \u017cyciu kom\u00f3rki. Biul. Pol. Tow. Onkol. Nowotw. 2019;4:220\u2013231."}, {"Citation": "Ho T., Tan B.X., Lane D. How the Other Half Lives: What P53 Does When It Is Not Being a Transcription Factor. Int. J. Mol. Sci. 2019;21:13. doi: 10.3390/ijms21010013.", "ArticleIdList": ["10.3390/ijms21010013", "PMC6982169", "31861395"]}, {"Citation": "Shang X., Lin K., Yu R., Zhu P., Zhang Y., Wang L., Xu J., Chen K. Resveratrol Protects the Myocardium in Sepsis by Activating the Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (MTOR) Pathway and Inhibiting the Nuclear Factor-\u039aB (NF-\u039aB) Signaling Pathway. Med. Sci. Monit. 2019;25:9290\u20139298. doi: 10.12659/MSM.918369.", "ArticleIdList": ["10.12659/MSM.918369", "PMC6911307", "31806860"]}, {"Citation": "Mohapatra P., Satapathy S.R., Das D., Siddharth S., Choudhuri T., Kundu C.N. Resveratrol Mediated Cell Death in Cigarette Smoke Transformed Breast Epithelial Cells Is through Induction of P21Waf1/Cip1 and Inhibition of Long Patch Base Excision Repair Pathway. Toxicol. Appl. Pharmacol. 2014;275:221\u2013231. doi: 10.1016/j.taap.2014.01.011.", "ArticleIdList": ["10.1016/j.taap.2014.01.011", "24467951"]}, {"Citation": "Podust V.N., Podust L.M., Goubin F., Ducommun B., H\u00fcbscher U. Mechanism of Inhibition of Proliferating Cell Nuclear Antigen-Dependent DNA Synthesis by the Cyclin-Dependent Kinase Inhibitor P21. Biochemistry. 1995;34:8869\u20138875. doi: 10.1021/bi00027a039.", "ArticleIdList": ["10.1021/bi00027a039", "7612628"]}, {"Citation": "Chen U., Chen S., Saha P., Dutta A. P21Cip1/Waf1 Disrupts the Recruitment of Human Fen1 by Proliferating-Cell Nuclear Antigen into the DNA Replication Complex. Proc. Natl. Acad. Sci. USA. 1996;93:11597\u201311602. doi: 10.1073/pnas.93.21.11597.", "ArticleIdList": ["10.1073/pnas.93.21.11597", "PMC38103", "8876181"]}, {"Citation": "Pastushenko I., Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2019;29:212\u2013226. doi: 10.1016/j.tcb.2018.12.001.", "ArticleIdList": ["10.1016/j.tcb.2018.12.001", "30594349"]}, {"Citation": "Jolly M.K., Tripathi S.C., Jia D., Mooney S.M., Celiktas M., Hanash S.M., Mani S.A., Pienta K.J., Ben-Jacob E., Levine H. Stability of the Hybrid Epithelial/Mesenchymal Phenotype. Oncotarget. 2016;7:27067\u201327084. doi: 10.18632/oncotarget.8166.", "ArticleIdList": ["10.18632/oncotarget.8166", "PMC5053633", "27008704"]}, {"Citation": "Pastushenko I., Brisebarre A., Sifrim A., Fioramonti M., Revenco T., Boumahdi S., Van Keymeulen A., Brown D., Moers V., Lemaire S., et al. Identification of the Tumour Transition States Occurring during EMT. Nature. 2018;556:463\u2013468. doi: 10.1038/s41586-018-0040-3.", "ArticleIdList": ["10.1038/s41586-018-0040-3", "29670281"]}, {"Citation": "Lamouille S., Xu J., Derynck R. Molecular Mechanisms of Epithelial-Mesenchymal Transition. Nat. Rev. Mol. Cell Biol. 2014;15:178\u2013196. doi: 10.1038/nrm3758.", "ArticleIdList": ["10.1038/nrm3758", "PMC4240281", "24556840"]}, {"Citation": "Shih J.-Y., Yang P.-C. The EMT Regulator Slug and Lung Carcinogenesis. Carcinogenesis. 2011;32:1299\u20131304. doi: 10.1093/carcin/bgr110.", "ArticleIdList": ["10.1093/carcin/bgr110", "21665887"]}, {"Citation": "Ji Q., Liu X., Han Z., Zhou L., Sui H., Yan L., Jiang H., Ren J., Cai J., Li Q. Resveratrol Suppresses Epithelial-to-Mesenchymal Transition in Colorectal Cancer through TGF-\u03921/Smads Signaling Pathway Mediated Snail/E-Cadherin Expression. BMC Cancer. 2015;15:97. doi: 10.1186/s12885-015-1119-y.", "ArticleIdList": ["10.1186/s12885-015-1119-y", "PMC4362662", "25884904"]}, {"Citation": "Li J., Wang Z., Li H., Cao J., Nan N., Zhai X., Liu Y., Chong T. Resveratrol Inhibits TRAF6/PTCH/SMO Signal and Regulates Prostate Cancer Progression. Cytotechnology. 2022;74:549\u2013558. doi: 10.1007/s10616-022-00544-0.", "ArticleIdList": ["10.1007/s10616-022-00544-0", "PMC9525528", "36238265"]}, {"Citation": "Yamashita M., Fatyol K., Jin C., Wang X., Liu Z., Zhang Y.E. TRAF6 Mediates Smad-Independent Activation of JNK and P38 by TGF-\u03b2. Mol. Cell. 2008;31:918\u2013924. doi: 10.1016/j.molcel.2008.09.002.", "ArticleIdList": ["10.1016/j.molcel.2008.09.002", "PMC2621323", "18922473"]}, {"Citation": "Rauf A., Imran M., Butt M.S., Nadeem M., Peters D.G., Mubarak M.S. Resveratrol as an Anti-Cancer Agent: A Review. Crit. Rev. Food Sci. Nutr. 2018;58:1428\u20131447. doi: 10.1080/10408398.2016.1263597.", "ArticleIdList": ["10.1080/10408398.2016.1263597", "28001084"]}, {"Citation": "Brown V.A., Patel K.R., Viskaduraki M., Crowell J.A., Perloff M., Booth T.D., Vasilinin G., Sen A., Schinas A.M., Piccirilli G., et al. Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis. Cancer Res. 2010;70:9003\u20139011. doi: 10.1158/0008-5472.CAN-10-2364.", "ArticleIdList": ["10.1158/0008-5472.CAN-10-2364", "PMC2982884", "20935227"]}, {"Citation": "Cai H., Scott E., Kholghi A., Andreadi C., Rufini A., Karmokar A., Britton R.G., Horner-Glister E., Greaves P., Jawad D., et al. Cancer Chemoprevention: Evidence of a Nonlinear Dose Response for the Protective Effects of Resveratrol in Humans and Mice. Sci. Transl. Med. 2015;7:298ra117. doi: 10.1126/scitranslmed.aaa7619.", "ArticleIdList": ["10.1126/scitranslmed.aaa7619", "PMC4827609", "26223300"]}, {"Citation": "Holcombe R.F., Martinez M., Planutis K., Planutiene M. Effects of a Grape-Supplemented Diet on Proliferation and Wnt Signaling in the Colonic Mucosa Are Greatest for Those over Age 50 and with High Arginine Consumption. Nutr. J. 2015;14:62. doi: 10.1186/s12937-015-0050-z.", "ArticleIdList": ["10.1186/s12937-015-0050-z", "PMC4472174", "26085034"]}, {"Citation": "Nguyen A.V., Martinez M., Stamos M.J., Moyer M.P., Planutis K., Hope C., Holcombe R.F. Results of a Phase I Pilot Clinical Trial Examining the Effect of Plant-Derived Resveratrol and Grape Powder on Wnt Pathway Target Gene Expression in Colonic Mucosa and Colon Cancer. Cancer Manag. Res. 2009;1:25\u201337.", "ArticleIdList": ["PMC3004662", "21188121"]}, {"Citation": "Howells L.M., Berry D.P., Elliott P.J., Jacobson E.W., Hoffmann E., Hegarty B., Brown K., Steward W.P., Gescher A.J. Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases\u2014Safety, Pharmacokinetics, and Pharmacodynamics. Cancer Prev. Res. 2011;4:1419\u20131425. doi: 10.1158/1940-6207.CAPR-11-0148.", "ArticleIdList": ["10.1158/1940-6207.CAPR-11-0148", "PMC3173869", "21680702"]}, {"Citation": "Ren B., Kwah M.X.-Y., Liu C., Ma Z., Shanmugam M.K., Ding L., Xiang X., Ho P.C.-L., Wang L., Ong P.S., et al. Resveratrol for Cancer Therapy: Challenges and Future Perspectives. Cancer Lett. 2021;515:63\u201372. doi: 10.1016/j.canlet.2021.05.001.", "ArticleIdList": ["10.1016/j.canlet.2021.05.001", "34052324"]}, {"Citation": "Sun X., Xu Q., Zeng L., Xie L., Zhao Q., Xu H., Wang X., Jiang N., Fu P., Sang M. Resveratrol Suppresses the Growth and Metastatic Potential of Cervical Cancer by Inhibiting STAT3Tyr705 Phosphorylation. Cancer Med. 2020;9:8685\u20138700. doi: 10.1002/cam4.3510.", "ArticleIdList": ["10.1002/cam4.3510", "PMC7666735", "33040485"]}, {"Citation": "Hao X., Sun X., Zhu H., Xie L., Wang X., Jiang N., Fu P., Sang M. Hydroxypropyl-\u03b2-Cyclodextrin-Complexed Resveratrol Enhanced Antitumor Activity in a Cervical Cancer Model: In Vivo Analysis. Front. Pharmacol. 2021;12:573909. doi: 10.3389/fphar.2021.573909.", "ArticleIdList": ["10.3389/fphar.2021.573909", "PMC8082405", "33935691"]}, {"Citation": "Sun X., Fu P., Xie L., Chai S., Xu Q., Zeng L., Wang X., Jiang N., Sang M. Resveratrol Inhibits the Progression of Cervical Cancer by Suppressing the Transcription and Expression of HPV E6 and E7 Genes. Int. J. Mol. Med. 2021;47:335\u2013345. doi: 10.3892/ijmm.2020.4789.", "ArticleIdList": ["10.3892/ijmm.2020.4789", "PMC7723400", "33236130"]}, {"Citation": "Chen Y., Ji N., Pan S., Zhang Z., Wang R., Qiu Y., Jin M., Kong D. Roburic Acid Suppresses NO and IL-6 Production via Targeting NF-\u039aB and MAPK Pathway in RAW264.7 Cells. Inflammation. 2017;40:1959\u20131966. doi: 10.1007/s10753-017-0636-z.", "ArticleIdList": ["10.1007/s10753-017-0636-z", "28761990"]}, {"Citation": "Xu H., Liu T., Li J., Chen F., Xu J., Hu L., Jiang L., Xiang Z., Wang X., Sheng J. Roburic Acid Targets TNF to Inhibit the NF-\u039aB Signaling Pathway and Suppress Human Colorectal Cancer Cell Growth. Front. Immunol. 2022;13:853165. doi: 10.3389/fimmu.2022.853165.", "ArticleIdList": ["10.3389/fimmu.2022.853165", "PMC8864141", "35222445"]}, {"Citation": "Wang G., Chen K., Ma C., Wang C., Chen D., He J., Liu Y., Jiang T., Yuan J., Chen L., et al. Roburic Acid Attenuates Osteoclastogenesis and Bone Resorption by Targeting RANKL-Induced Intracellular Signaling Pathways. J. Cell. Physiol. 2022;237:1790\u20131803. doi: 10.1002/jcp.30642.", "ArticleIdList": ["10.1002/jcp.30642", "34796915"]}, {"Citation": "Verhoff M., Seitz S., Paul M., Noha S.M., Jauch J., Schuster D., Werz O. Tetra- and Pentacyclic Triterpene Acids from the Ancient Anti-Inflammatory Remedy Frankincense as Inhibitors of Microsomal Prostaglandin E2 Synthase-1. J. Nat. Prod. 2014;77:1445\u20131451. doi: 10.1021/np500198g.", "ArticleIdList": ["10.1021/np500198g", "PMC4074212", "24844534"]}, {"Citation": "Cao H., Yu R., Choi Y., Ma Z.-Z., Zhang H., Xiang W., Lee D.Y.-W., Berman B.M., Moudgil K.D., Fong H.H.S., et al. Discovery of Cyclooxygenase Inhibitors from Medicinal Plants Used to Treat Inflammation. Pharmacol. Res. 2010;61:519\u2013524. doi: 10.1016/j.phrs.2010.02.007.", "ArticleIdList": ["10.1016/j.phrs.2010.02.007", "PMC2860736", "20188172"]}, {"Citation": "Stamatakos M., Palla V., Karaiskos I., Xiromeritis K., Alexiou I., Pateras I., Kontzoglou K. Cell Cyclins: Triggering Elements of Cancer or Not? World J. Surg. Oncol. 2010;8:111. doi: 10.1186/1477-7819-8-111.", "ArticleIdList": ["10.1186/1477-7819-8-111", "PMC3016250", "21176227"]}, {"Citation": "Kiliszek P., Juszczy\u0144ski P. Deregulation of BCL2 family proteins in B-cell lymphomas\u2014Molecular, pathogenetic, clinical and therapeutic implications. Hematol. Clin. Pract. 2012;3:288\u2013301."}, {"Citation": "Salvesen G.S., Riedl S.J. Caspase Mechanisms. Adv. Exp. Med. Biol. 2008;615:13\u201323. doi: 10.1007/978-1-4020-6554-5_2.", "ArticleIdList": ["10.1007/978-1-4020-6554-5_2", "18437889"]}, {"Citation": "Wang X., Xuetao X., Wu M., Wu P., Sheng Z., Liu W., Ma Y.-Y., Zhao D.-G., Zhang K., Li D., et al. Inhibitory Effect of Roburic Acid in Combination with Docetaxel on Human Prostate Cancer Cells. J. Enzym. Inhib. Med. Chem. 2022;37:542\u2013553. doi: 10.1080/14756366.2021.2018684.", "ArticleIdList": ["10.1080/14756366.2021.2018684", "PMC8741252", "34986722"]}, {"Citation": "Liu L., Lauro B.M., Ding L., Rovere M., Wolfe M.S., Selkoe D.J. Multiple BACE1 Inhibitors Abnormally Increase the BACE1 Protein Level in Neurons by Prolonging Its Half-Life. Alzheimer\u2019s Dement. 2019;15:1183\u20131194. doi: 10.1016/j.jalz.2019.06.3918.", "ArticleIdList": ["10.1016/j.jalz.2019.06.3918", "PMC6756967", "31416794"]}, {"Citation": "Wiese F., Kutschan S., Doerfler J., Mathies V., Buentzel J., Buentzel J., Huebner J. Green Tea and Green Tea Extract in Oncological Treatment: A Systematic Review. Int. J. Vitam. Nutr. Res. 2023;93:72\u201384. doi: 10.1024/0300-9831/a000698.", "ArticleIdList": ["10.1024/0300-9831/a000698", "33593083"]}, {"Citation": "Wang L., Li P., Feng K. EGCG Adjuvant Chemotherapy: Current Status and Future Perspectives. Eur. J. Med. Chem. 2023;250:115197. doi: 10.1016/j.ejmech.2023.115197.", "ArticleIdList": ["10.1016/j.ejmech.2023.115197", "36780831"]}, {"Citation": "Wan X., Wang W., Liang Z. Epigallocatechin-3-Gallate Inhibits the Growth of Three-Dimensional in Vitro Models of Neuroblastoma Cell SH-SY5Y. Mol. Cell. Biochem. 2021;476:3141\u20133148. doi: 10.1007/s11010-021-04154-w.", "ArticleIdList": ["10.1007/s11010-021-04154-w", "PMC8263418", "33860868"]}, {"Citation": "Masuda M., Suzui M., Weinstein I.B. Effects of Epigallocatechin-3-Gallate on Growth, Epidermal Growth Factor Receptor Signaling Pathways, Gene Expression, and Chemosensitivity in Human Head and Neck Squamous Cell Carcinoma Cell Lines. Clin. Cancer Res. 2001;7:4220\u20134229.", "ArticleIdList": ["11751523"]}, {"Citation": "Masuda M., Suzui M., Lim J.T.E., Deguchi A., Soh J.-W., Weinstein I.B. Epigallocatechin-3-Gallate Decreases VEGF Production in Head and Neck and Breast Carcinoma Cells by Inhibiting EGFR-Related Pathways of Signal Transduction. J. Exp. Ther. Oncol. 2002;2:350\u2013359. doi: 10.1046/j.1359-4117.2002.01062.x.", "ArticleIdList": ["10.1046/j.1359-4117.2002.01062.x", "12440226"]}, {"Citation": "Baliga M.S., Meleth S., Katiyar S.K. Growth Inhibitory and Antimetastatic Effect of Green Tea Polyphenols on Metastasis-Specific Mouse Mammary Carcinoma 4T1 Cells in Vitro and in Vivo Systems. Clin. Cancer Res. 2005;11:1918\u20131927. doi: 10.1158/1078-0432.CCR-04-1976.", "ArticleIdList": ["10.1158/1078-0432.CCR-04-1976", "15756018"]}, {"Citation": "Shin D.M., Nannapaneni S., Patel M., Shi Q., Liu Y., Chen Z., Chen A., El-Deiry M.W., Beitler J.J., Steuer C., et al. Phase 1B Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. Clin. Cancer Res. 2020;26:5860\u20135868. doi: 10.1158/1078-0432.CCR-20-2276.", "ArticleIdList": ["10.1158/1078-0432.CCR-20-2276", "PMC8016407", "32943457"]}, {"Citation": "Brockmueller A., Samuel S.M., Mazurakova A., B\u00fcsselberg D., Kubatka P., Shakibaei M. Curcumin, Calebin A and Chemosensitization: How Are They Linked to Colorectal Cancer? Life Sci. 2023;318:121504. doi: 10.1016/j.lfs.2023.121504.", "ArticleIdList": ["10.1016/j.lfs.2023.121504", "36813082"]}, {"Citation": "Giordano A., Tommonaro G. Curcumin and Cancer. Nutrients. 2019;11:2376. doi: 10.3390/nu11102376.", "ArticleIdList": ["10.3390/nu11102376", "PMC6835707", "31590362"]}, {"Citation": "Guo L., Chen X.-J., Hu Y.-H., Yu Z.-J., Wang D., Liu J.-Z. Curcumin Inhibits Proliferation and Induces Apoptosis of Human Colorectal Cancer Cells by Activating the Mitochondria Apoptotic Pathway. Phytother. Res. 2013;27:422\u2013430. doi: 10.1002/ptr.4731.", "ArticleIdList": ["10.1002/ptr.4731", "22628241"]}, {"Citation": "Kim G.-Y., Kim K.-H., Lee S.-H., Yoon M.-S., Lee H.-J., Moon D.-O., Lee C.-M., Ahn S.-C., Park Y.C., Park Y.-M. Curcumin Inhibits Immunostimulatory Function of Dendritic Cells: MAPKs and Translocation of NF-Kappa B as Potential Targets. J. Immunol. 2005;174:8116\u20138124. doi: 10.4049/jimmunol.174.12.8116.", "ArticleIdList": ["10.4049/jimmunol.174.12.8116", "15944320"]}, {"Citation": "Teiten M.-H., Dicato M., Diederich M. Hybrid Curcumin Compounds: A New Strategy for Cancer Treatment. Molecules. 2014;19:20839\u201320863. doi: 10.3390/molecules191220839.", "ArticleIdList": ["10.3390/molecules191220839", "PMC6271749", "25514225"]}, {"Citation": "Singh D.V., Agarwal S., Singh P., Godbole M.M., Misra K. Curcumin Conjugates Induce Apoptosis via a Mitochondrion Dependent Pathway in MCF-7 and MDA-MB-231 Cell Lines. Asian Pac. J. Cancer Prev. 2013;14:5797\u20135804. doi: 10.7314/APJCP.2013.14.10.5797.", "ArticleIdList": ["10.7314/APJCP.2013.14.10.5797", "24289580"]}, {"Citation": "Bordoloi D., Roy N.K., Monisha J., Padmavathi G., Kunnumakkara A.B. Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far. Recent Pat. Anticancer Drug Discov. 2016;11:67\u201397. doi: 10.2174/1574892810666151020101706.", "ArticleIdList": ["10.2174/1574892810666151020101706", "26537958"]}, {"Citation": "Devarajan N., Nathan J., Mathangi R., Mahendra J., Ganesan S.K. Pharmacotherapeutic Values of Berberine: A Chinese Herbal Medicine for the Human Cancer Management. J. Biochem. Mol. Toxicol. 2023;37:e23278. doi: 10.1002/jbt.23278.", "ArticleIdList": ["10.1002/jbt.23278", "36588295"]}, {"Citation": "Marthandam Asokan S., Mariappan R., Muthusamy S., Velmurugan B.K. Pharmacological Benefits of Neferine\u2014A Comprehensive Review. Life Sci. 2018;199:60\u201370. doi: 10.1016/j.lfs.2018.02.032.", "ArticleIdList": ["10.1016/j.lfs.2018.02.032", "29499283"]}, {"Citation": "Nejabati H.R., Roshangar L. Kaempferol: A Potential Agent in the Prevention of Colorectal Cancer. Physiol. Rep. 2022;10:e15488. doi: 10.14814/phy2.15488.", "ArticleIdList": ["10.14814/phy2.15488", "PMC9579739", "36259115"]}, {"Citation": "Merritt J.C., Richbart S.D., Moles E.G., Cox A.J., Brown K.C., Miles S.L., Finch P.T., Hess J.A., Tirona M.T., Valentovic M.A., et al. Anti-Cancer Activity of Sustained Release Capsaicin Formulations. Pharmacol. Ther. 2022;238:108177. doi: 10.1016/j.pharmthera.2022.108177.", "ArticleIdList": ["10.1016/j.pharmthera.2022.108177", "PMC9510151", "35351463"]}, {"Citation": "Namazi Sarvestani N., Sepehri H., Delphi L., Moridi Farimani M. Eupatorin and Salvigenin Potentiate Doxorubicin-Induced Apoptosis and Cell Cycle Arrest in HT-29 and SW948 Human Colon Cancer Cells. Asian Pac. J. Cancer Prev. 2018;19:131\u2013139. doi: 10.22034/APJCP.2018.19.1.131.", "ArticleIdList": ["10.22034/APJCP.2018.19.1.131", "PMC5844607", "29373904"]}, {"Citation": "Marupudi N.I., Han J.E., Li K.W., Renard V.M., Tyler B.M., Brem H. Paclitaxel: A Review of Adverse Toxicities and Novel Delivery Strategies. Expert Opin. Drug Saf. 2007;6:609\u2013621. doi: 10.1517/14740338.6.5.609.", "ArticleIdList": ["10.1517/14740338.6.5.609", "17877447"]}, {"Citation": "Chan A., Hertz D.L., Morales M., Adams E.J., Gordon S., Tan C.J., Staff N.P., Kamath J., Oh J., Shinde S., et al. Biological Predictors of Chemotherapy-Induced Peripheral Neuropathy (CIPN): MASCC Neurological Complications Working Group Overview. Support. Care Cancer. 2019;27:3729\u20133737. doi: 10.1007/s00520-019-04987-8.", "ArticleIdList": ["10.1007/s00520-019-04987-8", "PMC6728179", "31363906"]}, {"Citation": "Chhibber A., Mefford J., Stahl E.A., Pendergrass S.A., Baldwin R.M., Owzar K., Li M., Winer E.P., Hudis C.A., Zembutsu H., et al. Polygenic Inheritance of Paclitaxel-Induced Sensory Peripheral Neuropathy Driven by Axon Outgrowth Gene Sets in CALGB 40101 (Alliance) Pharm. J. 2014;14:336. doi: 10.1038/tpj.2014.2.", "ArticleIdList": ["10.1038/tpj.2014.2", "PMC4111770", "24513692"]}, {"Citation": "de Man F.M., Goey A.K.L., van Schaik R.H.N., Mathijssen R.H.J., Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin. Pharmacokinet. 2018;57:1229\u20131254. doi: 10.1007/s40262-018-0644-7.", "ArticleIdList": ["10.1007/s40262-018-0644-7", "PMC6132501", "29520731"]}, {"Citation": "Peeters M., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., Andr\u00e9 T., Chan E., Lordick F., Punt C.J.A., et al. Randomized Phase III Study of Panitumumab with Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared with FOLFIRI Alone as Second-Line Treatment in Patients with Metastatic Colorectal Cancer. J. Clin. Oncol. 2010;28:4706\u20134713. doi: 10.1200/JCO.2009.27.6055.", "ArticleIdList": ["10.1200/JCO.2009.27.6055", "20921462"]}, {"Citation": "Innocenti F., Undevia S.D., Ram\u00edrez J., Mani S., Schilsky R.L., Vogelzang N.J., Prado M., Ratain M.J. A Phase I Trial of Pharmacologic Modulation of Irinotecan with Cyclosporine and Phenobarbital. Clin. Pharmacol. Ther. 2004;76:490\u2013502. doi: 10.1016/j.clpt.2004.07.016.", "ArticleIdList": ["10.1016/j.clpt.2004.07.016", "15536463"]}, {"Citation": "Flieger D., Klassert C., Hainke S., Keller R., Kleinschmidt R., Fischbach W. Phase II Clinical Trial for Prevention of Delayed Diarrhea with Cholestyramine/Levofloxacin in the Second-Line Treatment with Irinotecan Biweekly in Patients with Metastatic Colorectal Carcinoma. Oncology. 2007;72:10\u201316. doi: 10.1159/000111083.", "ArticleIdList": ["10.1159/000111083", "17998785"]}, {"Citation": "la Porte C., Voduc N., Zhang G., Seguin I., Tardiff D., Singhal N., Cameron D.W. Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000 Mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects. Clin. Pharmacokinet. 2010;49:449\u2013454. doi: 10.2165/11531820-000000000-00000.", "ArticleIdList": ["10.2165/11531820-000000000-00000", "20528005"]}, {"Citation": "Popat R., Plesner T., Davies F., Cook G., Cook M., Elliott P., Jacobson E., Gumbleton T., Oakervee H., Cavenagh J. A Phase 2 Study of SRT501 (Resveratrol) with Bortezomib for Patients with Relapsed and or Refractory Multiple Myeloma. Br. J. Haematol. 2013;160:714\u2013717. doi: 10.1111/bjh.12154.", "ArticleIdList": ["10.1111/bjh.12154", "23205612"]}, {"Citation": "Nasibullin I., Smirnov I., Ahmadi P., Vong K., Kurbangalieva A., Tanaka K. Synthetic Prodrug Design Enables Biocatalytic Activation in Mice to Elicit Tumor Growth Suppression. Nat. Commun. 2022;13:39. doi: 10.1038/s41467-021-27804-5.", "ArticleIdList": ["10.1038/s41467-021-27804-5", "PMC8748823", "35013295"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "2", "Day": "2"}, {"Year": "2023", "Month": "3", "Day": "14"}, {"Year": "2023", "Month": "3", "Day": "20"}, {"Year": "2023", "Month": "4", "Day": "14", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "4", "Day": "13", "Hour": "1", "Minute": "16"}, {"Year": "2023", "Month": "4", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "3", "Day": "23"}], "PublicationStatus": "epublish", "ArticleIdList": ["37048059", "PMC10092955", "10.3390/cells12070986", "cells12070986"]}}], "PubmedBookArticle": []}